SOURCE: Applied DNA Sciences

Applied DNA Sciences

February 15, 2013 00:01 ET

DLA Activates Authentication Contract With Applied DNA Sciences

Supports Mandate by Agency for Use of SigNature® DNA on Electronics

STONY BROOK, NY--(Marketwire - Feb 15, 2013) - Applied DNA Sciences, Inc. (OTCBB: APDN), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced today the activation of an agreement with the Defense Logistics Agency for authentication services and training. Signed in November, the contract was activated with the delivery of the first services by APDN to DLA.

Authentication services and training, consisting of forensic analysis of DLA-procured parts with SigNature DNA marks, are in support of the DLA mandate requiring the use of SigNature DNA on microcircuits provided by trusted suppliers to DLA.

The year-long contract, with a maximum value of $150,000, represents APDN's first direct business with a federal U.S. government agency. APDN has participated in a two-phase pilot for DLA (generating about $1 million in total), however, that work was subcontracted through LMI, a not-for-profit consultancy which works with DLA.

The current mandate requiring SigNature DNA marking on microcircuits delivers to DLA the ability to check for parts authenticity or provenance. This contract enables DLA to have APDN forensically authenticate the DNA marked components.

About Applied DNA Sciences

APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA and smartDNA, our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.

The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 20, 2012 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Contact Information

  • MEDIA CONTACT:
    Mitchell Miller
    646-543-3373
    fax: 631-444-8848

    INVESTOR CONTACT:
    Debbie Bailey
    631-444-8090
    fax: 631-444-8848

    FCMN Contact: Email Contact
    Web site: http://www.adnas.com
    Twitter: @APDN, @APDNInvestor